צמיחת הכנסות ב-12 חודשים נגררים: I-Mab (IMAB)

I-Mab is undergoing a large-scale resource reallocation following a structural split, which maintains high risk volatility. The business model is based on selling antibody rights to Western corporations after primary testing in China, thereby minimizing capital expenditures. Success depends on the effectiveness of the immunotherapy portfolio and the regulatory environment. This chart of the rolling 12-month YoY revenue growth demonstrates real sales dynamics, where the indicator reached the level of 0.00.
I-Mab Biopharma - פילוחים אנליטיים ומדדי מפתח (IMAB)

To minimize risks, investors should track demand dynamics for I-Mab (IMAB) drugs, utilizing relative revenue growth over the last four quarters compared to the previous year as a filter for market cycles. Portfolio diversification of antibodies and global partnerships ensure stability, while an upward trend in this indicator confirms the actual expansion of the company's commercial presence, preventing overpayment for fading business development momentum.